Executive Summary / Key Takeaways

• Spero Therapeutics has fundamentally realigned its strategy, concentrating resources almost entirely on advancing its lead asset, tebipenem HBr, an oral carbapenem for complicated urinary tract infections (cUTIs), under its partnership with GSK (GSK).
• The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr was recently stopped early for efficacy following a positive review by the Independent Data Monitoring Committee, a significant de-risking event for the program.
• This strategic pivot follows setbacks with other pipeline candidates, including the suspension of the oral SPR720 program due to a failed interim analysis and safety signals, and the discontinuation of SPR206 development.
• Financially, Spero reported a net loss of $13.9 million in Q1 2025 and relies heavily on milestone payments from the GSK collaboration, which, along with existing cash, is expected to fund operations into Q2 2026; however, substantial doubt about the company's ability to continue as a going concern exists without further funding.
• The company faces significant risks, including dependence on GSK's successful regulatory and commercialization efforts, the need for additional capital beyond Q2 2026, potential Nasdaq delisting, and an ongoing SEC investigation related to prior disclosures.

A High-Stakes Pivot in the Fight Against Antibiotic Resistance

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to addressing the urgent global health threat of multi-drug resistant (MDR) bacterial infections and developing treatments for rare diseases. Founded in 2013, the company has built a pipeline of novel antibiotic candidates, navigating the complex landscape of drug development in a field often challenged by scientific hurdles, regulatory complexities, and commercial viability concerns. Spero's journey has been marked by strategic shifts, most recently culminating in a focused realignment around its lead asset, tebipenem HBr, an investigational oral carbapenem.

The core of Spero's current strategy centers on the potential of tebipenem HBr to transform the treatment paradigm for complicated urinary tract infections (cUTIs), including acute pyelonephritis. These infections represent a significant unmet medical need, particularly those caused by MDR pathogens, often requiring hospitalization and intravenous (IV) carbapenem therapy. Tebipenem HBr, if approved, could be the first broad-spectrum oral carbapenem available, offering the potential for outpatient treatment or earlier transition from IV to oral therapy, thereby reducing healthcare costs and improving patient convenience.

This strategic focus was solidified following a period of pipeline evaluation and restructuring. Historically, Spero pursued multiple candidates, including SPR720 for nontuberculous mycobacterial pulmonary disease (NTM-PD) and SPR206 for IV treatment of MDR Gram-negative infections. However, a planned interim analysis of the Phase 2a trial for the oral formulation of SPR720 in October 2024 did not meet its primary endpoint (change in bacterial load) and revealed potential dose-limiting safety signals (reversible grade 3 hepatotoxicity). This led to the suspension of the oral SPR720 program, with the company currently analyzing the full dataset to determine potential next steps, though an oral path for NTM-PD is now considered unlikely. Further, in March 2025, Spero discontinued development of SPR206, and the NIAID contract supporting this program was subsequently terminated for convenience in April 2025.

These decisions underscore the inherent risks and challenges in drug development and have concentrated Spero's efforts and resources squarely on the tebipenem HBr program.

Tebipenem HBr: The Central Pillar and Recent Breakthrough

The tebipenem HBr program gained significant momentum through a strategic partnership with GSK, established in November 2022. This collaboration granted GSK exclusive rights to develop, manufacture, and commercialize tebipenem HBr in most global territories, excluding certain Asian countries licensed to Meiji Seika Pharma. Under this agreement, Spero received an upfront payment and became eligible for substantial development, commercial, and sales-based milestones, plus tiered royalties on net sales.

A critical step forward for the program was the FDA's written agreement under a Special Protocol Assessment (SPA) in July 2023 on the design and size of the pivotal Phase 3 PIVOT-PO clinical trial. An SPA signals a high level of alignment between the FDA and the sponsor on the trial's design and planned analysis, suggesting that positive and persuasive results could support regulatory approval. This agreement significantly de-risked the regulatory pathway for tebipenem HBr.

The PIVOT-PO trial is a global, randomized, double-blind, double-dummy study comparing oral tebipenem HBr to IV imipenem-cilastatin in hospitalized adult patients with cUTIs. The primary endpoint is overall response (a composite of clinical cure and microbiological eradication) at the test of cure visit, with the primary analysis assessing non-inferiority. Enrollment commenced in Q4 2023 and was progressing as planned.

In a major development subsequent to the Q1 2025 financial reporting period, Spero and GSK announced in late May 2025 that the PIVOT-PO study was stopped early for efficacy based on a recommendation from the Independent Data Monitoring Committee following a pre-specified interim analysis of data from 1,690 patients. This outcome indicates that tebipenem HBr demonstrated statistically significant efficacy, meeting the primary endpoint ahead of full enrollment. This positive result is a pivotal de-risking event for the program and is expected to support GSK's planned submission of a New Drug Application (NDA) to the FDA in the second half of 2025.

Financial Performance and Liquidity: A Tightrope Walk

Spero's financial performance reflects its stage of development and reliance on partnership funding. For the three months ended March 31, 2025, the company reported a net loss of $13.9 million, an increase from the $12.7 million net loss in the same period of 2024.

Revenue streams primarily consist of collaboration revenue from the GSK agreement and grant revenue from government awards (like BARDA, though BARDA funding for tebipenem HBr decreased significantly in Q1 2025 compared to Q1 2024). Collaboration revenue saw a modest increase in Q1 2025, largely driven by the GSK partnership.

Operating expenses are dominated by research and development (R&D) costs. While total R&D expenses decreased in Q1 2025 compared to Q1 2024, this was primarily due to the winding down of activities for SPR720 and SPR206. Direct R&D costs for the tebipenem HBr program, however, increased, reflecting the ongoing activities in the large Phase 3 PIVOT-PO trial. General and administrative (G&A) expenses saw an increase, partly due to costs associated with retention programs implemented during the October 2024 restructuring.

As of March 31, 2025, Spero held $48.9 million in cash and cash equivalents. The company's liquidity is significantly bolstered by the structured development milestone payments from GSK related to the PIVOT-PO trial. Spero received the third of four equal semi-annual installments of a $95 million milestone in February 2025 and expects the final $23.8 million payment in Q3 2025.

Based on its current cash position and these expected non-contingent GSK milestone payments, Spero estimates its cash runway will extend into the second quarter of 2026. However, the company explicitly states that substantial doubt exists about its ability to continue as a going concern beyond this period without securing additional funding. Future funding will be necessary to support ongoing operations and potentially pursue any future development activities beyond the scope of the current GSK-funded trial. The company has access to a universal shelf registration statement, but its ability to raise capital through primary public offerings is currently limited by Nasdaq's "baby shelf" rules due to its public float size.

Competitive Landscape and Positioning

The market for treating bacterial infections, particularly MDR strains and rare diseases like NTM-PD, is highly competitive, featuring large pharmaceutical companies, specialty pharmaceutical firms, and biotechnology companies.

For tebipenem HBr, the competitive landscape includes established oral antibiotics for cUTI (like fluoroquinolones such as Levaquin and Cipro, and Bactrim), although resistance to these agents is increasing. It also competes with IV carbapenems (the current standard for many MDR cUTIs) and newer IV antibiotics approved for resistant Gram-negative infections (e.g., Zerbaxa, Recarbrio, Fetroja). Spero positions tebipenem HBr's oral formulation as a key differentiator, offering a significant convenience advantage over IV options. While pricing may be at a premium compared to older generics, the potential to reduce hospitalization costs could support market adoption, assuming favorable reimbursement policies.

In the NTM-PD space, where SPR720 was being developed, the standard of care involves prolonged, often poorly tolerated combination regimens of antibiotics. Competitors include companies developing novel agents or improved formulations for NTM-PD, such as Insmed (INSM) (with its approved inhaled product Arikayce for refractory NTM-PD). Spero aimed to differentiate SPR720 with a novel oral mechanism targeting first-line patients, but the recent clinical setback significantly alters its competitive standing in this area.

For SPR206, prior to discontinuation, it was positioned against existing polymyxins and newer IV agents for MDR Gram-negative infections, aiming for an improved safety profile. Large players like Pfizer (PFE) and Merck (MRK) have significant portfolios in this broader hospital-acquired infection space.

Overall, Spero's competitive strategy hinges on identifying and developing novel mechanisms or formulations that address specific unmet needs within infectious diseases. Its partnerships, particularly with GSK, are crucial for accessing the resources and expertise needed to compete against larger, more established players who possess significantly greater financial resources, R&D capabilities, and global commercial infrastructure. Spero's technological moat lies in the potential differentiation of its candidates (e.g., oral carbapenem, novel MOA), but translating this into commercial success requires navigating formidable development, regulatory, and market access hurdles against well-resourced competitors.

Risks and Challenges Ahead

Despite the recent positive news from the PIVOT-PO trial, Spero faces substantial risks. The most immediate include:

• Dependence on GSK: The company's prospects are now heavily reliant on GSK's successful execution of the remaining regulatory filing (NDA expected 2H 2025) and commercialization activities for tebipenem HBr. GSK has termination rights under the license agreement, and failure to achieve commercial success would significantly impact Spero's ability to realize value from the partnership.
• Funding Needs: The cash runway into Q2 2026 necessitates securing significant additional capital thereafter. Failure to raise funds on acceptable terms would force further spending reductions, potentially impacting any future development activities or even the ability to maintain operations. The "going concern" qualification highlights this critical financial uncertainty.
• Regulatory Approval: While the PIVOT-PO interim analysis is positive, final FDA approval is not guaranteed. The FDA will review the full data package, manufacturing processes, and labeling, and may still impose restrictions or require post-marketing studies.
• Market Acceptance: Even if approved, tebipenem HBr must gain acceptance from physicians, patients, and payors against established therapies and competitive products. Pricing and reimbursement will be key factors.
• Nasdaq Delisting: The company is currently non-compliant with Nasdaq's minimum bid price requirement and must regain compliance by August 2025 to avoid potential delisting, which could negatively impact stock liquidity and the ability to raise capital.
• SEC Investigation: The ongoing SEC investigation and Wells Notice related to prior disclosures create uncertainty and could result in significant costs, penalties, or other adverse outcomes, potentially impacting the business and stock price.
  \

Conclusion

Spero Therapeutics has undergone a significant strategic transformation, narrowing its focus to the tebipenem HBr program under the GSK partnership. The recent positive outcome from the PIVOT-PO Phase 3 interim analysis represents a major validation of this strategy and a critical step towards potential regulatory approval. If GSK successfully navigates the NDA process and commercializes tebipenem HBr, it could address a substantial unmet need in cUTI and provide significant future value to Spero through milestones and royalties.

However, the company operates from a position of financial vulnerability, with a limited cash runway and a stated going concern risk, necessitating further capital infusion beyond mid-2026. The success of the tebipenem program is now paramount, but it rests heavily on the execution and commercial capabilities of its partner, GSK. Investors should weigh the significant potential upside of tebipenem HBr's approval and commercial success against the company's precarious financial position, dependence on its partner, and other material risks, including the Nasdaq listing status and SEC investigation. The investment thesis is now largely a binary bet on the tebipenem HBr program's ultimate success in the market, enabled by the recent positive clinical data but constrained by financial realities and external dependencies.